Hercules Capital, Inc. Q1 2016 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2016. Hercules Capital, Inc. is an internally managed, non-diversified closed-end management investment company regulated as a Business Development Company (BDC) under the Investment Company Act of 1940. The Company focuses on providing senior secured loans to high-growth, venture capital-backed companies in technology, life sciences, and sustainable/renewable technology sectors. As of March 31, 2016, the Company held 73,230,000 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2016 | Q1 2015 |
|---|---|---|
| Total Assets | $1,331.8 million | $1,324.0 million (Dec 31, 2015) |
| Total Investments (at value) | $1,291.3 million | $1,200.6 million (Dec 31, 2015) |
| Net Investment Income | $20.1 million | $13.0 million |
| Net Realized Gain (Loss) | $(4.5) million | $3.3 million |
| Net Unrealized Appreciation (Depreciation) | $(1.3) million | $5.6 million |
| Net Increase in Net Assets from Operations | $14.3 million | $21.9 million |
| Net Asset Value (NAV) per Share | $9.81 | $9.94 (Dec 31, 2015) |
| Dividends Declared per Share | $0.31 | $0.31 |
| Total Debt Outstanding (Principal) | $611.5 million | $600.5 million (Dec 31, 2015) |
| Cash and Cash Equivalents | $13.5 million | $95.2 million (Dec 31, 2015) |
Material Changes vs. Prior Period
- Investment Portfolio Growth: The total fair value of the investment portfolio increased by approximately $90.7 million (7.6%) from December 31, 2015, driven by new fundings and restructures totaling $170.9 million.
- Net Investment Income: Increased 54.6% year-over-year to $20.1 million, primarily due to portfolio growth and higher weighted average principal outstanding.
- Realized Losses: The Company recorded a net realized loss of $4.5 million, compared to a gain of $3.3 million in Q1 2015. This was driven by gross realized losses of $7.3 million, largely due to the settlement of a debt investment in The Neat Company ($6.2 million) and write-offs of other portfolio companies.
- Unrealized Depreciation: Net unrealized depreciation of $1.3 million was recorded, contrasting with $5.6 million of appreciation in the prior year. This included $6.2 million of depreciation on equity investments (notably Box, Inc.) and $1.1 million on public warrants, partially offset by $6.0 million of appreciation on debt investments due to reversals of prior impairments.
- Liquidity: Cash and cash equivalents decreased significantly from $95.2 million to $13.5 million due to active investment deployment and dividend payments.
Guidance, Outlook, and Risks
- Dividend Policy: The Board declared a quarterly dividend of $0.31 per share, payable May 23, 2016. The Company intends to distribute approximately $8.2 million of spillover earnings from 2015 in 2016.
- Capital Resources: The Company maintains an At-The-Market (ATM) equity distribution agreement with approximately 6.2 million shares remaining available. A stock repurchase plan with $40.6 million remaining authorization is active through August 2016.
- Debt Facilities: The Wells Facility was expanded to $95.0 million in March 2016. The Convertible Senior Notes ($17.6 million principal) matured in April 2016 and were subsequently converted or repaid.
- Risks and Contingencies:
- Portfolio Company Distress: On May 2, 2016 (subsequent to period end), portfolio company BIND Therapeutics, Inc. filed for Chapter 11 bankruptcy. The Company believes the investment is secured and current on payments, leaving it on accrual status.
- Valuation Uncertainty: Approximately 97% of assets are Level 3 investments valued by the Board of Directors, subject to significant judgment and potential volatility.
- Interest Rate Sensitivity: 93.1% of the debt portfolio is floating rate, positioning the Company to benefit from rising rates.
Key Facts for Investor Verification
- NAV Decline: Verify the impact of the $6.2 million unrealized depreciation on public equity (Box, Inc.) and the $4.5 million net realized loss on the overall NAV trajectory.
- Debt Maturity Wall: Confirm the status of the $17.6 million Convertible Senior Notes which matured in April 2016 (subsequent events indicate full repayment/conversion).
- BIND Therapeutics Exposure: Review the specific terms of the senior secured loan to BIND Therapeutics following its Chapter 11 filing to assess potential impairment risks.
- Liquidity Position: Monitor the low cash balance ($13.5 million) relative to the $64.6 million in unfunded commitments and upcoming debt service obligations.
- Dividend Sustainability: Assess whether the $0.31 dividend is fully covered by taxable income given the realized losses and unrealized depreciation in the quarter.